CompletedNCT06259526
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Medication studyAges 18–65China
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Beijing and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 26, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 267
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06259526
- Official title
Show the full official title
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Get this study by email
Recruitment & locations
CompletedBeijing · Chongqing · Guangzhou
12 more locations
- Baoding
- Shijiazhuang
- Daqing
- Wuxi
- Zhenjiang
- Nanchang
- Siping
- Jinan
- Tianjin
- Ürümqi
- Kunming
- Huzhou
Questions about this study
Who is behind this study?
The study sponsor is Tasly Pharmaceutical Group Co., Ltd, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 high-dose group and Active drug group.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder